Paper · 42980888
Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.
Yan H and 1 other. Curr Treat Options Oncol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities. Papers, record 42980888. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42980888
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.
- Journal
- Curr Treat Options Oncol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-06
Source PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pancreatic Neoplasms | Major topic |
| Claudins | Major topic |
| Molecular Targeted Therapy | Major topic |
| Humans | |
| Biomarkers, Tumor | |
| Antibodies, Bispecific | |
| Treatment Outcome | |
| Immunoconjugates | |
| Clinical Trials as Topic |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41,930,337 | Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41930337 | PubMed |
| 2 | 41,969,434 | The claudin-18.2-CD3 bispecific antibody IBI389 exerts an antitumor effect on malignant tumors with positive claudin-18.2 expression by promoting T-cell infiltration and remodeling the tumor immune microenvironment. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41969434 | PubMed |
| 3 | 39,835,140 | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. | Front Immunol | 2024 | https://conductscience.org/library/papers/39835140 | PubMed |
| 4 | 40,615,715 | Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer. | Br J Cancer | 2025 | https://conductscience.org/library/papers/40615715 | PubMed |
| 5 | 39,637,967 | Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2. | Cancer Lett | 2025 | https://conductscience.org/library/papers/39637967 | PubMed |
| 6 | 41,019,366 | Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy. | iScience | 2025 | https://conductscience.org/library/papers/41019366 | PubMed |
| 7 | 40,233,718 | CAR-T therapy in solid tumors. | Cancer Cell | 2025 | https://conductscience.org/library/papers/40233718 | PubMed |
| 8 | 37,719,370 | Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. | Acta Pharm Sin B | 2023 | https://conductscience.org/library/papers/37719370 | PubMed |
| 9 | 38,448,606 | The present and future of bispecific antibodies for cancer therapy. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38448606 | PubMed |
| 10 | 42,294,061 | Signaling pathway mechanisms in pancreatic ductal adenocarcinoma tumor microenvironment and emerging targeting strategies for improved prognosis. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42294061 | PubMed |
1 to 10 of 51
See all 51 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42980888
GET https://conductscience.org/api/papers/v1/42980888/references?page=2